MAB3890
Anti-PPAR α Antibody
ascites fluid, Chemicon®
Synonym(s):
PPAR alpha
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
monoclonal
species reactivity
human, mouse
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunocytochemistry: suitable
western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... PPARA(5465)
General description
Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that can be activated by a variety of compounds including fibratus, thiazolidinediones, prostaglandins and fatty acids. Three PPAR subtypes, designated PPARα, PPARβ (also designated PPARδ) and PPARγ, have been described. PPARs promote transcription by forming heterodimers with members of the retinoid X receptor (RXR) family of steroid receptors and binding to specific DNA motifs termed PPAR-response elements (PPREs). PPARα is abundant in primary hepatocytes where it regulates the expression of proteins involved in fatty acid metabolism. PPARβ is the most widely distributed subtype and is often expressed at high levels. PPARγ is predominantly seen in adipose tissue where it plays a critical role in regulating adipocyte differentiation.
Specificity
Reacts with Peroxisome Proliferator Activated Receptor alpha (PPARalpha). No cross reactivity with PPARbeta or PPARgamma.
Immunogen
Synthetic peptide from amino acids 18-34 of mouse PPARalpha.
Application
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Use Anti-PPAR α Antibody (Mouse Monoclonal Antibody) validated in ELISA, WB, ICC to detect PPAR alpha also known as Peroxisome Proliferator Activated Receptor α.
Western blot: 1:500-1:5,000
Immunocytochemistry: 1:500-1:5,000
ELISA: 1:500-1:5,000
Optimal working dilutions must be determined by end user.
Immunocytochemistry: 1:500-1:5,000
ELISA: 1:500-1:5,000
Optimal working dilutions must be determined by end user.
Physical form
Ascites fluid. Liquid. Contains no preservative.
Storage and Stability
Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.
Analysis Note
Control
3T3 whole cell lysate
3T3 whole cell lysate
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hao-Yu Liu et al.
Frontiers in nutrition, 8, 711398-711398 (2021-11-02)
Scope: Disruptions of circadian rhythm cause metabolic disorders and are closely related to dietary factors. In this study, we investigated the interplays between the dietary conjugated linoleic acid (CLA)-induced hepatic steatosis and the circadian clock regulation, in association with lipid
Demin Cai et al.
Journal of cellular physiology, 236(6), 4387-4402 (2020-11-14)
Nonalcoholic-fatty-liver-disease (NAFLD) is the result of imbalances in hepatic lipid partitioning and is linked to dietary factors. We demonstrate that conjugated linoleic acid (CLA) when given to mice as a dietary supplement, induced an enlarged liver, hepatic steatosis, and increased
Malin Tordis Meyer et al.
International journal of molecular sciences, 22(15) (2021-08-08)
Salivary gland cancers are rare but aggressive tumors that have poor prognosis and lack effective cure. Of those, parotid tumors constitute the majority. Functioning as metabolic machinery contributing to cellular redox balance, peroxisomes have emerged as crucial players in tumorigenesis.
Bo Li et al.
Journal of molecular endocrinology, 53(3), 393-403 (2014-10-15)
The prevalence of non-alcoholic fatty liver disease (NAFLD), a condition characterized by an excessive accumulation of triglycerides (TGs) in hepatocytes, has dramatically increased globally during recent decades. MicroRNAs (miRs) have been suggested to play crucial roles in many complex diseases
Hao-Yu Liu et al.
Liver international : official journal of the International Association for the Study of the Liver, 42(6), 1449-1466 (2022-02-21)
Disruption of lipid metabolism is largely linked to metabolic disorders, such as hypercholesterolemia (HCL) and liver steatosis. While cholesterol metabolic re-programmers can serve as targets for relevant interventions. Here we explored the dietary conjugated linoleic acids (CLA)-induced HCL in mice
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service